AFREZZA
Drug
Mannkind Corporation
Total Payments
$12.6M
Transactions
103,472
Doctors
15,152
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.4M | 15,125 | 2,584 |
| 2023 | $4.8M | 15,291 | 3,659 |
| 2022 | $2.1M | 14,599 | 3,772 |
| 2021 | $903,316 | 15,805 | 3,340 |
| 2020 | $677,910 | 8,140 | 2,095 |
| 2019 | $507,288 | 11,690 | 3,236 |
| 2018 | $739,351 | 12,799 | 4,926 |
| 2017 | $457,210 | 10,023 | 4,194 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 5,586 | 61.9% |
| Food and Beverage | $1.8M | 92,210 | 14.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 1,251 | 13.0% |
| Consulting Fee | $811,870 | 318 | 6.4% |
| Travel and Lodging | $414,496 | 1,333 | 3.3% |
| Gift | $143,444 | 2,427 | 1.1% |
| Education | $5,450 | 344 | 0.0% |
| Charitable Contribution | $5,021 | 3 | 0.0% |
Payments by Type
Research
$7.8M
5,586 transactions
General
$4.8M
97,886 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INHALE-1 | Mannkind Corporation | $4.9M | 19 |
| INHALE-3 | Mannkind Corporation | $2.2M | 0 |
| Afrezza Safety and Pharmacokinetics Study in Pediatric Patients | Mannkind Corporation | $294,187 | 0 |
| Afrezza with Basal Combination (ABC) | Mannkind Corporation | $182,373 | 0 |
| DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza in Adult Subjects 18 Years and Older with Type 1 or Type 2 Diabetes Mellitus | Mannkind Corporation | $176,562 | 0 |
| AFREZZA WITH BASAL COMBINATION (ABC) | Mannkind Corporation | $133,762 | 0 |
| INHALE-1 | MannKind Corporation | $2,958 | 0 |
Top Doctors Receiving Payments for AFREZZA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Endocrinology, Diabetes & Metabolism | Roanoke, VA | $17,381 | 149 |
| , MD | Endocrinology, Diabetes & Metabolism | Santa Barbara, CA | $16,899 | 51 |
| , MD | Endocrinology, Diabetes & Metabolism | Knoxville, TN | $16,694 | 88 |
| , MD | Endocrinology, Diabetes & Metabolism | Elyria, OH | $16,662 | 124 |
| , MD | Internal Medicine | Frisco, TX | $16,516 | 208 |
| , MD | Endocrinology, Diabetes & Metabolism | Forest Hills, NY | $16,326 | 213 |
| , MD | Endocrinology, Diabetes & Metabolism | Newport Beach, CA | $15,526 | 36 |
| , M.D | Family Medicine | San Antonio, TX | $14,962 | 45 |
| , M.D | Internal Medicine | Yucaipa, CA | $14,457 | 76 |
| , MD | Endocrinology, Diabetes & Metabolism | Chapel Hill, NC | $14,361 | 19 |
| , MD | Endocrinology, Diabetes & Metabolism | Asheville, NC | $13,886 | 40 |
| , M.D | Internal Medicine | Garland, TX | $13,540 | 141 |
| , D.O | Endocrinology, Diabetes & Metabolism | Parkersburg, WV | $13,013 | 124 |
| , M.D | Endocrinology, Diabetes & Metabolism | Austin, TX | $12,819 | 29 |
| , MD | Endocrinology, Diabetes & Metabolism | Shavano Park, TX | $12,414 | 136 |
| , M.D | Endocrinology, Diabetes & Metabolism | Germantown, TN | $12,121 | 110 |
| , MD | Endocrinology, Diabetes & Metabolism | Williamsville, NY | $11,964 | 75 |
| , MD | Endocrinology, Diabetes & Metabolism | Forest Hills, NY | $11,944 | 83 |
| , M.D | Specialist | New York, NY | $11,869 | 57 |
| , M.D | Endocrinology, Diabetes & Metabolism | Greenville, NC | $11,732 | 91 |
| , M.D | Internal Medicine | Lubbock, TX | $11,539 | 209 |
| , M.D | Internal Medicine | Harlingen, TX | $11,366 | 42 |
| , MD | Endocrinology, Diabetes & Metabolism | Pittsburgh, PA | $11,194 | 37 |
| , MD | Endocrinology, Diabetes & Metabolism | New Orleans, LA | $11,160 | 12 |
| , MD | Internal Medicine | Melbourne, FL | $11,130 | 34 |
Ad
Manufacturing Companies
- Mannkind Corporation $10.5M
- MannKind Corporation $2.1M
Product Information
- Type Drug
- Total Payments $12.6M
- Total Doctors 15,152
- Transactions 103,472
About AFREZZA
AFREZZA is a drug associated with $12.6M in payments to 15,152 healthcare providers, recorded across 103,472 transactions in the CMS Open Payments database. The primary manufacturer is Mannkind Corporation.
Payment data is available from 2017 to 2024. In 2024, $2.4M was paid across 15,125 transactions to 2,584 doctors.
The most common payment nature for AFREZZA is "Unspecified" ($7.8M, 61.9% of total).
AFREZZA is associated with 7 research studies, including "INHALE-1" ($4.9M).